血液制品 行业,格局再度生变。在停牌两天之后, 派林生物 6月9日发布公告称,原实际控制人共青城胜帮英豪投资合伙企业(下称“胜帮英豪”),拟将其所持公司21.03%的股份全部出售给中国生物。不过,鉴于中国生物方面尚未完成对派林生物的全面尽职审查,目前双方还未敲定最终的交易价格,具体的交易条款将以最终达成的正式协议为准。公告显示,胜帮英豪的控股股东为陕西国资委,而中国生物隶属于 中国医药 集团。这...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.